Long-Term Treatment With Letrozole in a Boy With Familial Male-Limited Precocious Puberty

Xin Yuan, Ruimin Chen, Ying Zhang, Xiaohong Yang, Xiangquan LinFrontiers in Endocrinology 2022 · DOI

Abstract

A patrilineal mutation of the LHCGR gene has been identified in a boy with Familial Male-Limited Precocious Puberty (FMPP). Following a long-term treatment regimen involving letrozole, triptorelin, and spironolactone, the patient reached a height of 168.7 cm (-0.05 SD), successfully approaching his predicted adult height.

Introduction

Familial Male-Limited Precocious Puberty (FMPP), also known as testotoxicosis, is an exceptionally rare, gonadotropin-independent form of puberty. It is caused by a mutation in the LHCGR gene that keeps the luteinizing hormone receptor constitutively active, leading the testes to produce high levels of testosterone as early as age 2–4.

The primary clinical challenge in FMPP is that elevated testosterone levels—and their subsequent conversion into estrogen—cause rapid linear growth accompanied by even faster skeletal maturation. This results in premature fusion of the growth plates and a significantly stunted final adult height. While various treatments have been explored, long-term data on the safety and efficacy of third-generation aromatase inhibitors like letrozole remain limited. This case study details the successful 6.9-year management of a Chinese boy with FMPP.

Methods

The researchers conducted a longitudinal case study of a 3.1-year-old boy referred for peripheral precocious puberty. The clinical approach included:

  • Genetic Sequencing: Analysis of the LHCGR gene confirmed the diagnosis (p.Ala568Val mutation).
  • Hormonal Monitoring: Regular measurement of testosterone, LH, FSH, and other metabolic profiles.
  • Auxological Assessment: Tracking height and Bone Age (BA) every 3–6 months using the Greulich-Pyle method.
  • Combination Pharmacotherapy:
    • Letrozole: A third-generation aromatase inhibitor used to block the conversion of testosterone to estrogen, thereby slowing bone maturation.
  • Triptorelin (GnRHa): Added later to suppress "secondary central puberty" triggered by early sex steroid exposure.
  • Spironolactone: Added to antagonize androgen receptors when testosterone levels remained high.

Key Results

Over the 6.9-year treatment period, the patient gained 51.9 cm in height. The most significant achievement was the deceleration of bone maturation relative to chronological growth.

Growth chart illustrating the divergence between chronological age (black) and bone age (red) during treatment.

As shown in the growth chart, the patient's height according to bone age was initially severely advanced. The combination therapy effectively "decoupled" these metrics; while his chronological age increased by 6.9 years, his bone age increased by only 5.2 years.

Summary of clinical data, including height SDS and bone age progression over the 6.9-year follow-up.

By age 10, the patient reached a height of 168.7 cm. His height SDS (Standard Deviation Score) relative to adult norms reached -0.05 SD, aligning closely with his mid-parental target height of 165 cm. Throughout the nearly seven-year period, no drug-related severe adverse events or side effects were observed.

Discussion and Insights

This case highlights several critical aspects of FMPP management:

  • The Estrogen Factor: The study confirms that targeting estrogen production via aromatase inhibitors like letrozole is key to preventing premature growth plate fusion.
  • Secondary Central Puberty: Clinicians must remain vigilant for the onset of central puberty. Once the hypothalamus-pituitary-gonadal axis is activated by early peripheral steroids, the addition of a GnRH agonist (triptorelin) becomes necessary.
  • Potency of Letrozole: The results suggest letrozole may be particularly effective in suppressing estrogen and improving predicted adult height compared to earlier generation inhibitors like anastrozole.
  • Genotypic Variability: Interestingly, the patient’s father carried the same mutation but did not exhibit severe precocious puberty, suggesting the presence of modifying genetic or environmental factors.

Conclusion

This long-term follow-up demonstrates that a combination of letrozole, triptorelin, and spironolactone is a viable and safe strategy for managing FMPP. While the results are promising, the rarity of the condition necessitates further multi-center studies to establish a standardized global treatment protocol.

Summary updated

Abstract

A patrilineal mutation of the LHCGR gene has been identified in a boy with FMPP. His height is 168.7cm (-0.05SD) which is approaching his adult height after long-term treatment with letrozole, triptorelin, and spironolactone.
BibTeX
@inproceedings{yuan2022long,
  author = {Xin Yuan and Ruimin Chen and Ying Zhang and Xiaohong Yang and Xiangquan Lin},
  title = {{Long-Term Treatment With Letrozole in a Boy With Familial Male-Limited Precocious Puberty}},
  booktitle = {Frontiers in Endocrinology},
  year = {2022},
  doi = {10.3389/fendo.2022.906852},
}
Figure